SARS-CoV-2 epitope mapping on microarrays highlights strong immune-response to N protein region
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
A workflow for SARS-CoV-2 epitope discovery on peptide microarrays is herein reported. The process started with a proteome-wide screening of immunoreactivity based on the use of a high-density microarray followed by a refinement and validation phase on a restricted panel of probes using microarrays with tailored peptide immobilization through a click-based strategy. Progressively larger, independent cohorts of Covid-19 positive sera were tested in the refinement processes, leading to the identification of immunodominant regions on SARS-CoV-2 Spike (S), Nucleocapsid (N) protein and Orf1ab polyprotein. A summary study testing 50 serum samples highlighted an epitope of the N protein (region 155-171) providing 92% sensitivity and 100% specificity of IgG detection in Covid-19 samples thus being a promising candidate for rapid implementation in serological tests.
Article activity feed
-
SciScore for 10.1101/2020.11.09.374082: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The study was approved by the ethic committee of IRCCS Sacro Cuore Don Calabria Hospital and study subjects provided written informed consent.
Consent: The study was approved by the ethic committee of IRCCS Sacro Cuore Don Calabria Hospital and study subjects provided written informed consent.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources The second incubation were performed with secondary antibody (Anti-Human IgG-Cy3, Jackson ImmunoReserarch; Anti-Human IgM-Cy5, Invitrogen) diluted in ratio 1:1000 in incubation buffer with 1% BSA. Anti-Human …SciScore for 10.1101/2020.11.09.374082: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The study was approved by the ethic committee of IRCCS Sacro Cuore Don Calabria Hospital and study subjects provided written informed consent.
Consent: The study was approved by the ethic committee of IRCCS Sacro Cuore Don Calabria Hospital and study subjects provided written informed consent.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources The second incubation were performed with secondary antibody (Anti-Human IgG-Cy3, Jackson ImmunoReserarch; Anti-Human IgM-Cy5, Invitrogen) diluted in ratio 1:1000 in incubation buffer with 1% BSA. Anti-Human IgG-Cy3suggested: NoneAnti-Human IgM-Cy5suggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- No funding statement was detected.
- No protocol registration statement was detected.
-